Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus
Authors:
- L. C. W. LitLLL. C. W. Lit
- L. S. TamLTL. S. Tam
- E. K. LiELE. K. Li
- C. W. K. LamCLC. W. K. Lam
Open Access
- 3 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 44 (8) , 989-994
Abstract
Objective. The costimulatory interactions of the B7 family molecules CD80 and CD86 on antigen-presenting cells with their T-cell counter-receptors CD28 and CTLA-4 modulate T lymphocyte-mediated immune responses in a reciprocal manner. We investigated the possible aberrant production of soluble (s) forms of the T-cell costimulatory molecules CD80, CD86, CD28 and CTLA-4 in plasma of patients with systemic lupus erythematosus (SLE), an autoimmune disease arising from T-lymphocyte dysregulation. Methods. Plasma concentration and ex vivo production of soluble costimulatory molecules of 79 SLE patients with or without active disease and 40 sex- and age-matched healthy subjects were measured by enzyme-linked immunosorbent assay. Results. Plasma sCTLA-4, sCD28, sCD80 and sCD86 concentrations of all SLE patients were significantly higher than concentrations in control subjects (all P<0.01). These increases were observed even in patients with inactive disease [SLE Disease Activity Index (SLEDAI) r = 0.228, P = 0.043). Upon mitogen treatment of peripheral blood mononuclear cells, the percentage increases in ex vivo production of sCD28 and sCD80 and the percentage decrease in sCTLA-4 release were all significantly smaller in SLE patients with active disease than in healthy subjects (P<0.01, P<0.05 and P<0.0001, respectively). Conclusion. The aberrant production of soluble T-cell costimulatory molecules is important in the immunopathogenesis of SLE, which occurs by the dysregulation of T-lymphocyte costimulation. Plasma sCTLA concentration could potentially serve as a surrogate marker of SLE disease activity.Keywords
This publication has 39 references indexed in Scilit:
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003
- Targeting T cell costimulation in autoimmune diseaseExpert Opinion on Therapeutic Targets, 2002
- Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2001
- A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cellsEuropean Journal of Immunology, 1999
- Identification of Three Alternatively Spliced Variants of Human CD28 mRNABiochemical and Biophysical Research Communications, 1999
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Treatment of Murine Lupus with CTLA4IgScience, 1994
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- CTLA-4 is a second receptor for the B cell activation antigen B7.Journal of Experimental Medicine, 1991